Janux Therapeutics, Inc.

NasdaqGM:JANX Stok Raporu

Piyasa değeri: US$878.8m

Janux Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Janux Therapeutics CEO'su David Campbell, Jun2017 tarihinde atandı, in görev süresi 8.92 yıldır. in toplam yıllık tazminatı $ 13.51M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5% maaş ve 95% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.37% ine doğrudan sahiptir ve bu hisseler $ 3.23M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 4.7 yıldır.

Anahtar bilgiler

David Campbell

İcra Kurulu Başkanı

US$13.5m

Toplam tazminat

CEO maaş yüzdesi5.03%
CEO görev süresi8.9yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi2yrs
Yönetim Kurulu ortalama görev süresi4.7yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • May 13

Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts

Celebrations may be in order for Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders, with the analysts delivering a...
Analiz Makalesi • May 11

Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Janux Therapeutics, Inc. ( NASDAQ:JANX ) came out with its quarterly results last week, and we wanted to see how the...
Seeking Alpha • May 04

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Summary Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation. Despite early-stage pipeline risks and near-term volatility, JANX’s cash position and platform progress justify a high-risk, long-term investment thesis. Read the full article on Seeking Alpha
Analiz Makalesi • Oct 08

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analiz Makalesi • Apr 23

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Dec 03

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Summary Janux Therapeutics' TRACTr platform shows promise with encouraging early data, but the high valuation for a phase 1 company makes it a risky investment. The PSMA-targeted JANX007 has shown significant PSA reductions and partial tumor responses, but long-term efficacy and safety remain uncertain. JANX has a strong cash position, reducing immediate financial risks, but the market's high expectations could lead to severe valuation drops if data disappoints. Despite potential buyout rumors, the unproven nature of JANX's technology and the high market cap lead me to maintain a “Strong Sell” rating. Read the full article on Seeking Alpha
Analiz Makalesi • Oct 01

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 01

Janux Therapeutics: Buoyed By Buyout Speculation

Summary Today, we take another look at clinical stage biotech concern Janux Therapeutics, whose stock has soared in 2024. The shares have been buoyed throughout most of 2024 by a bevy of buyout speculation and some promising early-stage trial data. The company has a robust balance sheet and is targeting some potentially large markets. However, the company's pipeline is early-stage and there was some significant insider selling in the stock in early June at near all-time highs. Can the rally in Janux Therapeutics continue? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Jul 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 11

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Summary Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes. I recommend a cautious 'Buy' for JANX, highlighting its speculative nature, potential risks in drug development, and competition in the mCRPC market. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Summary Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032. Positive preliminary data also observed for the other phase 1a study using JANX008 for the treatment of patients with EGFR expressing solid tumors. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 24

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Dec 29

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Key Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity...
Analiz Makalesi • Nov 04

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Jul 20

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analiz Makalesi • May 23

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Insights The projected fair value for Janux Therapeutics is US$15.07 based on 2 Stage Free Cash Flow to Equity...
Analiz Makalesi • Feb 09

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Oct 19

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 09

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics press release (NASDAQ:JANX): Q2 GAAP EPS of -$0.41. Collaboration Revenue of $2.37M. The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022
Analiz Makalesi • Jun 05

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Feb 19

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Nov 03

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO Tazminat Analizi

David Campbell'un ücretlendirmesi Janux Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$114m

Dec 31 2025US$14mUS$680k

-US$114m

Sep 30 2025n/an/a

-US$102m

Jun 30 2025n/an/a

-US$106m

Mar 31 2025n/an/a

-US$78m

Dec 31 2024US$9mUS$646k

-US$69m

Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$44m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$625k

-US$58m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$67m

Dec 31 2022US$6mUS$550k

-US$63m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$8mUS$459k

-US$33m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$812kUS$405k

-US$7m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 13.51M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.71M ).

Tazminat ve Kazançlar: David şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

David Campbell (65 yo)

8.9yrs
Görev süresi
US$13,506,231
Tazminat

Dr. David Campbell, Ph D serves as President, Chief Executive Officer Co-Founder and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific ca...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
David Campbell
President8.9yrsUS$13.51m0.37%
$ 3.2m
Thomas Diraimondo
Chief Scientific Officer2.3yrsUS$4.35m0.17%
$ 1.5m
Janeen Doyle
Chief Corporate & Business Development Officer1yrUS$4.67mVeri yok
Matt Whitmire
Vice President of Finance1.8yrsVeri yokVeri yok
Maria Dobek
Vice President of Accounting1.8yrsVeri yok0.0080%
$ 70.2k
Charles Winter
Chief Technical Officer3.3yrsUS$1.61m0.099%
$ 871.4k
James Pennington
General Counsel & Corporate Secretary4.8yrsVeri yokVeri yok
William Go
Chief Medical Officerless than a yearVeri yokVeri yok
2.0yrs
Ortalama Görev Süresi
48yo
Ortalama Yaş

Deneyimli Yönetim: JANX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David Campbell
President8.9yrsUS$13.51m0.37%
$ 3.2m
Vickie Capps
Independent Director5.2yrsUS$389.22k0.12%
$ 1.0m
Ronald Barrett
Independent Chairperson4.7yrsUS$420.78k0.0041%
$ 36.0k
Eric Dobmeier
Independent Director1.8yrsUS$376.09k0.00020%
$ 1.8k
Mark Davis
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Alana McNulty
Independent Director4.7yrsUS$379.84k0.0041%
$ 36.0k
Julie Michele Cherrington
Member of Scientific Advisory Board1.1yrsVeri yokVeri yok
Alessandra Cesano
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Natasha Hernday
Independent Director1.8yrsUS$374.22k0%
$ 0
Sheila Gujrathi
Independent Director5.2yrsUS$370.47k0.19%
$ 1.7m
Winston Kung
Independent Director3.7yrsUS$379.84k0.0041%
$ 36.0k
Jake Simson
Independent Director5.2yrsUS$381.59k0%
$ 0
4.7yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: JANX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/22 09:58
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Janux Therapeutics, Inc. 23 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Etzer DaroutBarclays
Alec StranahanBofA Global Research
Suranjit MukherjeeBTIG